Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Phase: PHASE4
Conditions: Heart Failure
Sponsor: Duke University

Amgen Proprietary - Confidential
PRIME-HF 
Confidential 
Version 3 – July 19, 2017 
1
PredischaRge Initiation of Ivabradine in the Management of 
Heart Failure (PRIME-HF) 
Date: July 19, 2017 
Version: 3 
NCT02827500
Principal Investigator: Robert J. Mentz, MD 
Duke Clinical Research Institute 
CONFIDENTIALITY STATEMENT 
The information contained in this document is the property or under control of DUKE CLINICAL 
RESEARCH INSTITUTE (DCRI) and is provided to you in confidence as an investigator, potential 
investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or 
Independent Ethics Committee.  The information is only to be used by you in connection with the clinical 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
2
study described in the protocol.  You will not disclose any of the information to others without written 
authorization from DCRI. 
 
 
 
 
Protocol Version and Amendment Tracking 
Version Number/Amendment 
Approval Date 
 
 
Version 1  
May 2, 2016 
Version 2 
June 29, 2016 
Version 3 
July 19, 2017 
 
 
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
3
Protocol Synopsis 
Name of Study Sponsor 
Dr. Robert Mentz, Duke Clinical Research Institute 
Product 
Ivabradine 
Protocol Title 
Predischarge Initiation of Ivabradine in the Management of 
Heart Failure 
Main Criteria for Inclusion 
Acute HF hospitalization 
Study Objective 
To test the primary hypothesis that, compared with usual care, 
a treatment strategy of initiation of ivabradine prior to 
discharge for a hospitalization for acute HF will result in a 
greater proportion of participants using ivabradine at 180 days. 
To explore barriers to acquisition of new HF therapies in 
routine clinical practice.   
Study Design 
A multi-center, patient-level, randomized, open-label study of 
180 days duration following index hospitalization in 
approximately 450 patients.  
Treatment Regimen 
Pre-discharge initiation of twice-daily oral ivabradine (starting 
at 5mg BID with encouraged dose titration to 7.5mg BID) 
versus usual care (i.e., post-discharge initiation of ivabradine at 
discretion of routine physician) for 180 days. Patients 
randomized to pre-discharge ivabradine who are not able to 
afford medication will enter a registry of ivabradine-eligible 
paitents with documentation of medication acquisition 
challenges. 
Duration of Study Participation 
180 days 
Number of Subjects 
Approximately 450 
Number of Sites 
Approximately 50 US 
Primary Endpoint 
Proportion of participants taking ivabradine at 180 days 
Secondary Endpoints 
Heart Rate Assessments: change in heart rate from baseline to 
180 days; heart rate at 180 days; and proportion of patients 
with heart rate < 70 bpm at 180 days 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
4
Name of Study Sponsor 
Dr. Robert Mentz, Duke Clinical Research Institute 
Product 
Ivabradine 
Changes in symptoms and quality of life from baseline to 180 
days by KCCQ and PGA 
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
5
Table of Contents 
 
Protocol Version and Amendment Tracking ...................................................................2 
Protocol Synopsis..........................................................................................................3 
Table of Contents ..........................................................................................................5 
Abbreviations................................................................................................................9 
Executive Summary .................................................................................................... 10 
1 
Introduction ..................................................................................................... 16 
1.1 
Background .......................................................................................... 16 
1.2 
Prior data.............................................................................................. 17 
1.3 
Rationale .............................................................................................. 18 
2 
Objectives........................................................................................................ 19 
2.1 
Primary Objective ................................................................................. 19 
2.2 
Secondary Objectives............................................................................ 19 
2.3 
Tertiary Objectives ............................................................................... 19 
3 
Subject Selection ............................................................................................. 21 
3.1 
Study Population .................................................................................. 21 
3.2 
Inclusion Criteria .................................................................................. 21 
3.3 
Exclusion Criteria ................................................................................. 22 
4 
Study Design ................................................................................................... 24 
4.1 
Overview of Study ................................................................................ 24 
4.2 
Screening Phase.................................................................................... 24 
4.3 
Clinical Evaluation Prior to Randomization ........................................... 24 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
6
4.4 
Randomization ..................................................................................... 25 
Figure 1. Study Flow Diagram ..................................................................................... 26 
 
26 
Figure 2. Schematic of Study Design ........................................................................... 27 
4.5 
Treatment Arms.................................................................................... 27 
4.6 
Patient Safety and Concomitant Medical Therapy .................................. 27 
5 
Study Procedures ............................................................................................. 29 
5.1 
Screening and Prerandomization Procedures .......................................... 29 
5.2 
Baseline Evaluations ............................................................................. 29 
5.3 
Treatment Intervention.......................................................................... 29 
5.4 
Follow-up Evaluations .......................................................................... 30 
5.4.1 
Clinical Follow-up Visit (Study Visit 1) .................................. 30 
Table 1. Recommended Dose Adjustments for Patients Taking Ivabradine  .................... 30 
5.4.2 
Clinical Follow-up Visit (Study Visit 2) .................................. 30 
5.4.3 
Phone Call.............................................................................. 31 
5.4.4 
Final Study Visit (Study Visit 3) ............................................. 31 
5.5 
Schedule of Assessments ...................................................................... 33 
6 
Enrollment and Randomization......................................................................... 34 
6.1 
Enrollment............................................................................................ 34 
6.2 
Randomization ..................................................................................... 34 
7 
Participant safety ............................................................................................. 35 
7.1 
Patient Safety and Concomitant Therapies ............................................. 35 
7.2 
Institutional Review Boards .................................................................. 35 
7.3 
Informed Consent ................................................................................. 35 
7.4 
Study Discontinuation........................................................................... 35 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
7
8 
Adverse Event Reporting and Follow-up........................................................... 37 
8.1 
Safety ................................................................................................... 37 
8.2 
Definitions............................................................................................ 37 
8.2.1 
Events of Interest.................................................................... 37 
8.3 
Protocol Specific Exceptions to SAE Reporting ..................................... 38 
8.3.1 
Suspected Adverse Reaction ................................................... 38 
8.4 
Assessment of Adverse Event Severity .................................................. 39 
8.5 
Assessment of Causal Relationship........................................................ 39 
8.6 
Expectedness ........................................................................................ 40 
8.7 
Adverse Event Reporting ...................................................................... 40 
8.8 
Serious Adverse Events......................................................................... 40 
8.9 
Pregnancy............................................................................................. 41 
8.10 
Withdrawal of Subjects from Study ....................................................... 41 
9 
Summary of clinical events .............................................................................. 42 
10 
Statistical Analysis Plan and Determination of Sample Size............................... 43 
10.1 
Overview.............................................................................................. 43 
10.2 
Sample Size Justification ...................................................................... 43 
10.3 
Analysis of the Primary Endpoint .......................................................... 44 
10.4 
Analysis of Secondary and Tertiary Endpoints ....................................... 44 
10.5 
Interim Analyses................................................................................... 45 
11 
Data Monitoring and Quality Control................................................................ 46 
11.1 
Required Data....................................................................................... 46 
11.2 
Data Collection and Tracking ................................................................ 46 
12 
Study Responsibilities ...................................................................................... 48 
12.1 
Investigator Responsibility/Performance................................................ 48 
12.2 
Study Data Reporting and Processing .................................................... 48 
12.3 
Training ............................................................................................... 48 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
8
12.4 
Monitoring the Investigational Sites ...................................................... 49 
12.5 
Study Documentation............................................................................ 50 
12.6 
Source Documentation .......................................................................... 50 
12.7 
Protocol Deviations .............................................................................. 52 
12.8 
Data Transmittal and Record Retention ................................................. 52 
12.9 
Study Closeout ..................................................................................... 53 
12.10 Audit/Inspections.................................................................................. 53 
12.11 Publication Policies .............................................................................. 53 
13 
Ethical Considerations...................................................................................... 54 
13.1 
Informed Consent ................................................................................. 54 
13.2 
Confidentiality of Subjects .................................................................... 54 
13.3 
Authorization for Use and Disclosure of Protected Health Information 
(HIPAA) .............................................................................................. 55 
13.4 
Human Subject Protections ................................................................... 55 
13.4.1 
Research Subject Selection and Justification of Exclusions ...... 55 
13.4.2 
Risks/Discomforts of Study Participation ................................ 55 
13.5 
Institutional Review Board/Ethics Committee Review ........................... 55 
13.6 
Steering Committee .............................................................................. 56 
13.7 
Data and Safety Monitoring Board ........................................................ 56 
14 
Appendices ...................................................................................................... 57 
Appendix A. Safety Considerations.............................................................................. 57 
Appendix B. Cardiomyopathy Questionnaire and Patient Global Assessment ................ 58 
References .................................................................................................................. 59 
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
9
Abbreviations 
bpm 
Beats per minute 
DSMB 
Data Safety Monitoring Board 
ECG 
Electrocardiogram 
HF 
Heart Failure 
HFrEF 
Heart failure with reduced ejection fraction 
IRB 
Institutional Review Board 
IV 
Intravenous 
KCCQ 
Kansas City Cardiomyopathy Questionnaire 
LVEF 
Left Ventricular ejection fraction 
NYHA 
New York Heart Association 
PGA 
Patient Global Assessment 
 
 
 
 
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
10 
 
Executive Summary 
Title 
PredischaRge initiation of Ivabradine in ManagEment of Heart Failure (PRIME-
HF) 
Patient 
Population 
Post-Acute Heart Failure Syndrome with left ventricular ejection fraction (LVEF) 
<35%, New York Heart Association (NYHA) class II-IV symptoms despite 
guideline-directed medical therapy, documented clinical stability, and sinus rhythm 
with a resting heart rate of >70 beats per minute (bpm).  
Location 
Approximately 50 clinical centers in the United States 
Brief Rationale 
Heart failure (HF) affects over 5 million adults in the United States alone and the 
prevalence is expected to increase.1 Despite promising advances in the treatment of 
chronic heart failure with reduced ejection fraction (HFrEF),2 patient outcomes 
remain poor, especially after a hospitalization for HF, and there is an unmet need for 
novel treatment strategies. Previous data also suggest that the hospital setting may 
provide a unique opportunity for patients with HF to initiate guideline-directed 
medical therapy.3 
Ivabradine is an orally available, specific inhibitor of the If current in the sinoatrial 
node recently approved for use for patients with HFrEF by the Food and Drug 
Administration. A double-blind, randomized, placebo-controlled trial demonstrated 
that heart-rate reduction with ivabradine improves clinical outcomes for patients with 
chronic, symptomatic HF.4 The initiation of ivabradine specifically in patients 
following stabilization for acute HF has not been evaluated. 
Since ivabradine was FDA approved relatively recently, this study also serves as a 
strategy trial to explore drug acquisition for a drug that has been proven efficacious 
to the heart failure population and has been added to 2016 ACC/AHA/HFSA 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
11 
guidelines, however, has not been adopted broadly into clinical practice. Ivabradine 
is not being provided for this study. Data are being captured to assess the number of 
subjects able to obtain ivabradine pre and post discharge as well as the barriers to 
obtaining ivabradine and reasons for non-initiation. 
Study Design 
A multi-center, patient-level, randomized, open-label study of 180 days duration 
following index hospitalization in approximately 450 patients. Given barriers to 
adoption of relatively novel therapeutics into clinical practice, those patients who are 
randomized to pre-discharge ivabradine but are not able to afford medication will 
enter a registry of ivabradine-eligible patients with documentation of the medication 
acquisition challenges experienced by the patient and provider. 
Treatment 
Pre-discharge initiation of twice-daily oral ivabradine (starting at 5mg BID with 
encouraged dose titration to 7.5mg BID) versus usual care (i.e., post-discharge 
initiation of ivabradine at discretion of routine physician) for 180 days.  
Primary 
Objective 
To test the primary hypothesis that, compared with usual care, a treatment strategy of 
initiation of ivabradine prior to discharge for a hospitalization for acute HF will be 
associated with a greater proportion of participants using ivabradine at 180 days.  
Secondary 
Objectives 
To assess the impact of predischarge initiation of ivabradine on: 
1) Heart Rate 
a) Change in heart rate from baseline to 180 days 
b) Median heart rate at 180 days 
2) Patient-Centered Outcomes  
a) Kansas City Cardiomyopathy Questionnaire  (KCCQ) 
b) Patient Global Assessment (PGA) 
Tertiary 
Objectives 
To explore the impact of predischarge initiation of ivabradine on: 
1) Evidence-Based Implementation 
a) Assessments of beta-blocker use at 180 days (e.g., proportion on beta-
blocker, proportion on target dose, mean change in dose) 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
12 
b) Other assessments of ivabradine use at 180 days (e.g., mean dose, proportion 
with any initiation, proportion on maximum dose) 
i) Evaluations will incorporate data based on whether or not indication 
status was retained and whether or not an ivabradine prescription was 
provided. 
2) Tolerability of ivabradine and events of interest 
a) Symptomatic bradycardia 
b) Symptomatic hypotension 
c) Other symptoms leading to ivabradine discontinuation 
To explore barriers to ivabradine acquisition in routine clinical practice. 
Summary of 
Clinical Events 
1) Worsening HF defined as hospital admission for worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as an 
outpatient 
2) All-cause mortality 
Primary 
Endpoint 
Proportion of participants taking ivabradine at 180 days. 
Secondary 
Endpoints 
1) Heart Rate Assessments 
a) Change in heart rate from baseline to 180 days 
b) Heart rate at 180 days 
c) Proportion of patients with heart rate <70bpm at 180 days 
2) Changes in symptoms and quality of life from baseline to 180 days as assessed 
by: 
a) KCCQ 
b) PGA 
Tertiary 
Endpoints 
1) Beta-blocker use at 180 days as assessed by the (a) proportion of participants on 
a beta-blocker at 180-days, (b) proportion on target dose, (c) the proportion 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
13 
discontinuing beta-blockers at 180 days and (d) the mean change in beta-blocker 
dose from discharge to 180 days 
2) Ivabradine use at 180 days as assessed by the (a) proportion of appropriate 
participants with any initiation of ivabradine at 180 days, (b) the proportion of 
appropriate participants at the maximum dose of ivabradine at 180 day (i.e., 7.5 
mg twice daily), and (c) the mean dose of ivabradine achieved at 180 days 
3) Tolerability of ivabradine and events of interest: 
a) Symptomatic bradycardia 
b) Symptomatic hypotension 
c) Other symptoms leading to ivabradine discontinuation  
4) Summary of barriers to acquisition of ivabradine. 
Summary of 
Clinical Events 
1) Worsening HF defined as hospital admission for worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as an 
outpatient 
2) All-cause mortality 
Abbreviated 
Study Flow 
1) Patients with a reduced LVEF (<35%) will be identified during a hospitalization 
with acute HF. Patients will be screened throughout the hospital stay though 
heart rate will specifically be assessed following stabilization. 
2) Prior to discharge, clinical stability will be assessed including blood pressure and 
heart rate criteria. Patients with a pre-discharge blood pressure of >90/50 mm Hg 
and heart rate > 70 bpm will be eligible and consent will be obtained. Subject 
should not have a planned/scheduled up-titration of beta-blocker in the following 
4 weeks. However, adjustments of background therapy can be made at any point 
during the study period at the discretion of the treating physician. Patients can be 
consented and randomized prior to the day of discharge as long as they meet 
entry criteria. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
14 
3) Consented patients will undergo baseline examination, KCCQ, and PGA. 
Baseline heart rate will be assessed on at least one 12-lead ECG (screening ECG 
may be used). 
4) Participants will then be randomized to predischarge initiation of ivabradine or 
usual care. Randomization will be stratified by clinical site.  
5) Participants randomized to predischarge initiation of ivabradine should receive at 
least the initial dose of 5mg BID prior to discharge from the hospital if possible. 
6) If the patient is randomized to pre-discharge initiation, the study team and/or 
inpatient care team (e.g., providers and care coordinator) should initiate the 
process to acquire outpatient medication, explore patient costs and consider 
support options for the patient. If the patient is not able to pay for the medication, 
they will continue in the study and will enter a registry of ivabradine-eligible 
patients with documentation of the medication acquisition challenges 
experienced by the patient and provider. 
7) Consistent with current HF guidelines,2 all participants should have a follow-up 
visit within 7-14 days of hospital discharge. Heart rate and systolic blood 
pressure will be assessed at this clinical visit. For participants randomized to 
predischarge initiation of ivabradine and on ivabradine 5mg BID,  the heart rate 
may be used to adjust the dose the dose to 2.5mg BID or 7.5mg BID. For 
participants randomized to usual care, ivabradine may be initiated at the 
provider’s discretion. 
8) All participants will have a second follow-up study visit 6 weeks (42 +/- 14 days) 
post-discharge. Heart rate, systolic blood pressure and quality of life (KCCQ and 
PGA) will be assessed. For participants already taking ivabradine in either 
treatment group, the heart rate may again be used to adjust the dose of 
ivabradine. For participants not yet receiving ivabradine, it may be initiated at the 
provider’s discretion.  
9) All participants will receive a 90 (+/-7) day post-discharge phone call by site to 
assess for event status and tolerability of ivabradine. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
15 
10) All participants will have a final study visit at 180 (+/-14) days post-discharge. 
Heart rate (on exam and 1 ECG), systolic blood pressure and quality of life 
(KCCQ and PGA) will be assessed. The treating physician may initiate 
ivabradine per usual care clinical practice.  

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
16 
1 
INTRODUCTION 
1.1 
Background 
Heart failure is a major public health issue. More than 5 million Americans have HF and 
the prevalence is expected to increase as the population ages and survival from coronary, 
hypertensive, and valvular heart disease improves.1,5 Data from randomized clinical trials 
have established the efficacy of a number of medical and device therapies for patients 
with chronic HFrEF,2 but patient outcomes remain poor, especially after a hospitalization 
for heart failure. The 1-year mortality rate after a HF hospitalization is 20-30%, and this 
number has been relatively unchanged over the past decade.6,7 These data suggest that 
there is an unmet need for novel treatment strategies and supports the assessment of 
new approaches in the post-acute HF setting. 
There is also wide variation in the implementation of clinical trial evidence into 
routine practice. Previous data highlight a multi-year gap between the generation of new 
evidence through clinical trials and the adoption of the data into routine clinical 
practice.8,9 This gap in care translates into many unnecessary deaths and hospitalizations 
each year for patients with HFrEF.10 While there are multiple reasons for this quality gap, 
clinical inertia has most often been noted as a major barrier. Ivabradine have been 
approved for use in Europe for several years11 for patients with symptomatic chronic 
HFrEF (LVEF <35%) and a heart rate >75 bpm on guideline-directed medical therapy (or 
intolerance/contra-indication to beta-blocker use). Ivabradine was recently approved for 
use in the United States. However, no US data exist regarding the potential adoption of 
ivabradine into routine clinical care. 
Since ivabradine is a newly approved drug, this study also serves as a strategy 
trial to challenge study sites to explore drug acquisition for a drug that has been proven 
efficacious to the heart failure population and has been added to 2016 ACC/AHA/HFSA 
guidelines, however, has not been adopted rapidly into clinical practice. Ivabradine is not 
being provided for this study. Data are being captured to assess the number of subjects 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
17 
who were able to obtain ivabradine pre and post discharge as well as the barriers to 
acquisition. 
Previous data for patients with HFrEF suggest that the hospital setting may 
provide a unique opportunity for patients to initiate guideline-directed medical therapy. 
In the Initiation Management Predischarge: Process for Assessment of Carvedilol 
Therapy in HF (IMPACT-HF) study, patients with an LVEF<40% hospitalized for HF 
that were started on carvedilol prior to hospital discharge were more likely to be on a 
beta-blocker at 60 days post-randomization compared to those receiving usual care.3 
These improvements in care were achieved without increasing side effects or index 
hospitalization length of stay. Similar to beta-blockers and other medical therapies for 
HF, ivabradine was initially studied in patients with chronic HF.4 The initiation of 
ivabradine specifically in patients following stabilization for acute HF has not been 
evaluated. 
1.2 
Prior data 
The Systolic Heart failure treatment with Ivabradine Trial (SHIFT) enrolled 6,558 
patients with chronic, symptomatic heart failure with reduced ejection fraction.4 In this 
double-blind, randomized, placebo-controlled trial, patients treated with ivabradine were 
less likely to experience the primary composite endpoint of cardiovascular death or 
hospitalization for HF (HR 0.82, 95% CI 0.75, 0.90). These results support that 
ivabradine represents a novel treatment strategy for patients with HFrEF already on 
optimal medical therapy including a beta-blocker. 
A prior study of data from the Organized Program to Initiate Lifesaving 
Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registry suggest 
that a substantial proportion of patients hospitalized with HFrEF have an elevated heart 
rate at discharge.12 This study analyzed 10,696 hospitalizations of patients with acute HF 
from United States hospitals with a LVEF <40%. Patients with a history of atrial 
arrhythmia or with a pacemaker or cardiac resynchronization therapy were excluded. At 
the time of discharge, the median heart rate was 72 bpm (interquartile range, 65-80 bpm) 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
18 
for patients on high-dose beta-blockers and increased to 80 bpm (interquartile range, 70-
89 bpm) for patients on no beta-blockers. Most patients, 7647 (71%), had a discharge 
heart rate of >70 bpm, including 1460 of 2301 patients (63%) discharged on >50% of 
target dose of beta-blocker therapy. 
1.3 
Rationale 
Outcomes for patients with HFrEF remain poor after a hospitalization for HF, and there is 
an unmet need for novel treatment strategies in HF. Previous data suggest that the 
hospital setting may provide a unique opportunity for patients with HF to initiate 
guideline-directed medical therapy.3 
A double-blind, randomized, placebo-controlled trial demonstrated that heart-rate 
reduction with ivabradine improves clinical outcomes for patients with chronic, 
symptomatic HF4,  but the initiation of ivabradine in patients following stabilization for 
acute HF has not been evaluated. 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
19 
2 
OBJECTIVES 
The primary hypothesis of the PRIME-HF study is that, compared with usual care, a 
treatment strategy of initiation of ivabradine prior to discharge for a hospitalization for 
acute HF will be associated with a greater proportion of participants using ivabradine at 
180 days.  
2.1 
Primary Objective 
To test the primary hypothesis that, compared with usual care, a treatment strategy of 
initiation of ivabradine prior to discharge for a hospitalization for acute HF will be 
associated with a greater proportion of participants using ivabradine at 180 days.  
2.2 
Secondary Objectives 
To assess the impact of predischarge initiation of ivabradine on: 
1) Heart Rate 
a) Change in heart rate from baseline to 180 days 
b) Median heart rate at 180 days 
2) Patient-Centered Outcomes  
a) Kansas City Cardiomyopathy Questionnaire  (KCCQ) 
b) Patient Global Assessment (PGA) 
2.3 
Tertiary Objectives 
Tertiary objectives will be to explore the impact of predischarge initiation of ivabradine 
on: 
1) Other assessments of evidence-based implementation of ivabradine and beta-blockers 
at 180 days. Evaluations will incorporate data based on whether or not indication 
status was retained and whether or not an ivabradine prescription was provided. 
2) Tolerability of ivabradine based on  events of interest during study follow-up: 
a) Symptomatic bradycardia 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
20 
b) Symptomatic hypotension 
c) Other symptoms leading to ivabradine discontinuation 
3) To explore barriers to the acquisition of ivabradine. 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
21 
3 
SUBJECT SELECTION 
3.1 
Study Population 
Patients suitable for this protocol are individuals with chronic HF who are hospitalized 
with acute heart failure, have achieved clinical stability and have an LVEF<35% and 
heart-rate >70 bpm in normal sinus rhythm. Subjects should not have a 
planned/scheduled uptitration of beta-blocker in the following 4 weeks. Adjustments of 
background therapy can be made at any point during the study period at the discretion of 
the attending physician. 
3.2 
Inclusion Criteria 
To be eligible for the study subject must meet the inclusion criteria listed below: 
1) Hospitalized with acute HF  (primary or secondary diagnosis) based on clinician 
assessment  
2) A prior clinical diagnosis of HF (i.e., not a new diagnosis of heart failure during 
the current hospitalization) 
3) Most recent LVEF ≤ 35% and within 6 months of randomization or LVEF ≤ 25% 
within 12 months of randomization 
4) On optimal guideline-directed medical therapy for HFrEF (or previously deemed 
intolerant) as determined by the clinician including ACE-inhibitors or angiotensin 
receptor antagonists or neprilysin inhibition, aldosterone receptor antagonists, and 
maximally-tolerated doses of beta-blockers at the time of current evaluation 
(which may differ from long-term targets) 
 Maximally-tolerated doses of beta-blockers will be defined by the treating 
physician when considering aspects such as current dose relative to the target 
dose used in clinical trials, patient heart rate and blood pressure, and patient 
symptoms   
 Patients with intolerance or contraindication to beta-blocker use are eligible 
for enrollment (details will be documented in the case report form) 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
22 
5) Age >18 years 
6) Willingness to provide informed consent from the subject (or at the discretion of 
the local IRB, the subject’s  guardian or legally authorized representative [LAR])   
7) On the day of planned randomization, all participants: 
 Must be in sinus rhythm with a resting heart rate >70 bpm as measured on  
ECG or a 10 second rhythm strip 
 Must have a blood pressure of >90/50 mm Hg 
3.3 
Exclusion Criteria 
If a subject meets any of the following criteria, he or she cannot be enrolled in the study: 
1) Documented plan for uptitration of beta-blocker in the following 4 weeks 
2) Permanent atrial fibrillation or atrial flutter 
3) Patients with recent atrial fibrillation or flutter defined by either precipitating the 
current HF hospitalization or occurring during the current HF hospitalization 
4) History of untreated sick sinus syndrome, sinoatrial block, or second and third 
degree atrio-ventricular block 
5) Pacemaker with atrial or ventricular pacing (except biventricular pacing) >40% of 
the time 
6) Family history or congenital long QT syndrome  
7) Recent myocardial infarction (<2 months prior to screening) [troponin elevation 
secondary to acute HF as determined by the clinician is not an exclusion] 
8) Acute or chronic severe liver disease as evidenced by any of the following: 
encephalopathy, variceal bleeding, INR > 1.7 in the absence of anticoagulation 
treatment  
9) Creatinine clearance <15 mL/min within 48 hours of screening that was not due to 
acute kidney injury that resolved 
10) Planned mechanical circulatory support within 180 days 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
23 
11) Pregnant or breastfeeding women. Women of child-bearing potential should use 
effective contraception 
12) Medical conditions likely to lead to poor non-cardiac survival at 180 days (e.g., 
cancer) 
13) Inability to comply with planned study procedures  
14) If the following medications are needed at inclusion or during the study: 
a) Non-dihydropyridine calcium channel blockers (e.g., diltiazem and verapamil) 
b) Class I anti-arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin) 
c) Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some 
macrolide antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, 
antiretroviral drugs (e.g., ritonavir, nelfinavir), and systemic azole antifungal 
agents (e.g., ketoconazole, itraconazole), and nefazodone 
d) Inducers of cytochrome P450 3A4 (CYP3A4) including St. John’s wort, 
rifampicin, barbiturates, and phenytoin. 
e) Treatments known to be associated with significant prolongation of the QT 
interval, including sotalol 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
24 
4 
STUDY DESIGN 
4.1 
Overview of Study 
The PRIME-HF study is a multi-center, patient-level, randomized, open-label study of 
approximately 450 patients with reduced LVEF of <35% and heart-rate >70 bpm who are 
being discharged from the hospital following stabilization from acute HF and will be 
randomized to a treatment strategy of predischarge initiation of ivabradine or usual care.  
4.2 
Screening Phase 
Patients admitted with acute HF will be screened for basic entry criteria. To be eligible, 
patients should be hospitalized with acute HF (primary or secondary diagnosis). Patients 
hospitalized with acute HF will be treated with standard therapy at the discretion of the 
treating physician including adjustment of guideline-directed medical therapies such as 
beta-blockers. Patients will be screened for potential eligibility during the index 
hospitalization but study inclusion criteria including clinical stability, heart rate, and 
blood pressure will be assessed once the patient is stable and approaching discharge. 
Patients can be consented and randomized prior to the day of discharge as long as they 
meet entry criteria. 
4.3 
 Clinical Evaluation Prior to Randomization 
When patients are approaching the time for discharge, final study eligibility will be 
determined. Prior to discharge, clinical stability will be assessed to ensure resolution of 
signs and symptoms of acute HF. Blood pressure and resting heart rate will be assessed. 
Patients with a pre-discharge blood pressure of >90/50 mm Hg and heart rate > 70 bpm 
will be eligible and approached for consent. Subjects should not have a 
planned/scheduled uptitration of beta-blocker in the following 4 weeks. Willing 
participants meeting entry criteria will provide written informed consent. Baseline heart 
rate must be ≥70bpm on ECG or a 10-second rhythm strip. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
25 
4.4 
 Randomization 
After signing the informed consent form, all subjects who fulfill all of the inclusion 
criteria and none of the exclusion criteria will be randomized. All patients will be 
randomized using an electronic system in a 1:1 allocation ratio to either predischarge 
initiation of ivabradine or usual care. Randomization will be stratified by clinical site.  
 
 
 
 
 
 
 
 
 
 
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
26 
Figure 1. Study Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening  
 
LVEF<35% and hospitalized for acute HF (primary or secondary diagnosis) 
 
Treated with standard therapy at the discretion of the treating physician including beta-blockers 
Patient Deemed Eligible for Discharge 
 
Obtain informed consent 
 
BP > 90/50 mm hg and sinus rhythm with a resting heart rate >70 bpm on a 12-lead ECG or 10-second rhythm strip  
 
Obtain baseline exam, KCCQ, PGA (obtain ECG if not already completed in screening) 
Baseline/Randomization (Day 0) 
 
1:1 randomization to predischarge initiation of ivabradine or usual care 
Predischarge Initiation (n=225) 
Usual Care (n=225) 
In-Hospital Monitoring 
 
Patients randomized to predischarge initiation receive 1st dose of 
ivabradine 5mg BID prior to hospital discharge. Explore medication costs 
and options to support patient. 
Post-discharge Follow-up (7-14 days post-
discharge) (Follow up Visit 1) 
 
Assess current medication use/doses, heart 
rate, KCCQ, PGA, event status 
 
Dose titration of ivabradine 
Week 6 Follow-up Visit (42 ± 14 days) (Follow up Visit 2) 
 
Assess current medication use/doses, heart rate, KCCQ, PGA, event status 
 
If participant now on ivabradine: 
o 
If heart rate <50 or symptomatic bradycardia, decrease ivabradine dose  
o 
If heart rate 50-60, maintain ivabradine dose 
o 
If heart rate >60, increase ivabradine dose 
 
If participant not on ivabradine, it may be initiated at the provider’s discretion 
Day 90 Phone Call (± 7 days) (Follow up Phone Call) 
 
Assess current heart failure medication use/doses, event status and tolerability of ivabradine in all participants 
Day 180 Follow-up Visit (± 14 days) (Follow up Visit 3) 
 
Assess current medication use/doses, heart rate via ECG, KCCQ, PGA, event status, and the final dose of ivabradine prior to the visit  
Post-discharge Follow-up (7-14 days post-
discharge) (Follow up Visit 1) 
 
Assess current medication use/doses, heart 
rate, KCCQ, PGA, event status 
 
Ivabradine may be initiated at the 
provider’s discretion 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
27 
Figure 2. Schematic of Study Design 
 
4.5 
Treatment Arms 
The treatment arms for this study are pre-discharge initiation of twice-daily oral 
ivabradine (starting at 5mg BID with encouraged dose titration to 7.5mg BID) versus 
usual care (i.e., post-discharge initiation of ivabradine at discretion of routine physician) 
for 180 days. 
4.6 
Patient Safety and Concomitant Medical Therapy 
Patients will receive standard medical therapy throughout the study. Adjustments of 
background therapy can be made at any point during the study period at the discretion of 
the attending physician. Therapy may include diuretics, ACE-inhibitors or ARBs, 
neprilysin inhibition, beta-blockers, and mineralocorticoid receptor antagonists. Patients 
may have adjustments of beta-blocker therapies up until 24 hours prior to 
randomization and still be eligible for the study. Subject should not have a 
planned/scheduled uptitration of beta-blocker in the following 4 weeks. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
28 
Sites will report  events of interest to include SAEs related to Ivabradine, Pregnancy, or 
lactation exposure.  Additional details are found in Section 8. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
29 
5 
STUDY PROCEDURES 
5.1 
Screening and Prerandomization Procedures 
Potentially eligible subjects will be identified from inpatient admissions and screened by 
interview. Interested subjects will be asked to give written informed consent and undergo 
a screening evaluation to include a complete history, physical examination, and laboratory 
tests. Study personnel will assess each subject against each inclusion and each exclusion 
criterion, and the investigator will determine the subject’s eligibility for study participation. 
The informed consent process and all assessments will be documented in the subject’s 
medical record.  
5.2 
Baseline Evaluations 
At the baseline visit and the time of randomization (prior to administration of ivabradine), 
all study participants will undergo the following: 
 History and physical examination 
 Baseline heart rate assessment via ECG (if ECG not already obtained in 
screening) 
 KCCQ and PGA 
5.3 
Treatment Intervention 
Participants randomized to predischarge initiation of ivabradine should receive the first 
dose of medication prior to discharge if possible. If ivabradine is administered and then 
discharge is delayed, participants should continue on open-label ivabradine until hospital 
discharge. Participants should then receive a prescription for outpatient ivabradine. Study 
drug will not be provided as part of the study. If the patient is randomized to pre-
discharge initiation, the study team and/or inpatient care team (e.g., providers and care 
coordinator) should initiate the process to acquire outpatient medication, explore patient 
costs and consider support options for the patient. If the patient is not able to pay for the 
medication, they will continue in the study and will enter a registry of ivabradine-eligible 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
30 
patients with documentation of the medication acquisition challenges experienced by the 
patient and provider. All participants will be counseled on the signs and symptoms of 
bradycardia including lightheadedness, dizziness, and syncope. Participants will also be 
followed carefully for the remainder of the hospitalization and monitored for adverse 
events including bradycardia or recurrence of heart failure signs or symptoms.  
5.4 
Follow-up Evaluations 
5.4.1 Clinical Follow-up Visit (Study Visit 1) 
Consistent with current HF guidelines,2 all participants should have a follow-up study 
visit within 7-14 days of hospital discharge. The timing of this visit will be determined by 
treating physicians. Current medication use and doses, physical examination, heart rate, 
systolic blood pressure and quality of life (KCCQ and PGA) will be assessed at this 
clinical visit. For participants randomized to predischarge initiation of ivabradine and on 
5mg BID, the heart rate may be used to adjust the dose of ivabradine to 2.5mg BID or 
7.5mg BID (Table 1). For participants randomized to usual care, ivabradine may be 
initiated at the provider’s discretion. Participants not eligible for ivabradine at this visit 
will be documented and continue study follow-up.  
Table 1. Recommended Dose Adjustments for Patients Taking Ivabradine  
Heart Rate 
Dose Adjustment 
>60 bpm 
Increase dose by 2.5 mg (given twice daily) up to a maximum 
dose of 7.5mg twice daily 
50-60 bpm 
Maintain current dose 
<50 bpm or signs and 
symptoms of bradycardia 
Decrease dose by 2.5mg (given twice daily); if current dose is 
2.5 mg twice daily, then discontinue therapy 
5.4.2 Clinical Follow-up Visit (Study Visit 2) 
At 6 weeks (42 +/- 14 days) post-discharge, all participants will have follow-up study 
visit. The study visit will include an assessment of current medication use and doses, 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
31 
physical examination,  heart rate, and systolic blood pressure. For participants on 
ivabradine, the heart rate may be used to adjust the dose (Table 1). For participants with a 
resting heart rate >60 bpm, the dose may be increased to either 5mg or 7.5mg BID. If the 
resting heart rate is <50 bpm or the participant is experiencing signs or symptoms related 
to bradycardia, then the dose may be reduced to 2.5mg BID or the study drug should be 
discontinued. If the heart rate is 50 to 60 bpm, then the dose may be maintained. For 
participants not yet taking ivabradine, then it may be initiated at the provider’s discretion. 
Participants not eligible for ivabradine at this visit will be documented and continue study 
follow-up. Study investigators or designee will assess quality of life (KCCQ and PGA).  
5.4.3  Phone Call 
At 90 (+/-7) days post-discharge, participants should be contacted by the site (phone call)  
to assess for event status, current medication use and doses, and tolerability of ivabradine, 
specifically 
 
 Symptomatic bradycardia 
 
Symptomatic hypotension 
 
Other symptoms leading to ivabradine discontinuation 
  
5.4.4  Final Study Visit (Study Visit 3) 
At 180 (+/- 14) days post discharge, all participants will have a routine clinic visit. The 
visit will include an assessment of current medication use and doses, physical 
examination including heart rate assessment (by exam and 1 ECG), and systolic blood 
pressure. The final dose of ivabradine prior to the visit will be recorded. Participants 
never initiated on or eligible for ivabradine will also be recorded. The study investigators 
or designee will assess quality of life (KCCQ and PGA).  
 
Using the  study schedule of assessments, provider-determined heart rate will be assessed 
at the following time points: baseline, post-discharge clinical follow-up visit (within 7-14 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
32 
days of hospital discharge), week 6, and day 180. Patient quality of life assessment will 
be assessed at the following time points: baseline, post-discharge clinical follow-up visit 
(within 7-14 days of hospital discharge), week 6, and day 180. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
33 
5.5 
Schedule of Assessments 
 
 
 
 
 
 
 
 
 
Baseline 
Time (Day) 
Pre-discharge 
Day 7-14 
post 
discharge 
6 Weeks post-
discharge  
(42 +/- 14 
days) 
90 Days post-
discharge  
(+/-7 days) 
180 Days 
post-
discharge 
(+/- 14 days) 
 
 
 
 
 
 
Visit 
Baseline/Randomization FU Visit 
1 
FU Visit 2 
FU Phone 
Call 
FU Visit 3 
Subject consent 
X 
 
 
 
 
Medical History 
X 
 
 
 
 
Physical examination 
X 
X 
X 
 
X 
Vital signs (HR,BP) 
X 
X 
X 
 
X 
ECG  
X 
 
 
 
X 
KCCQ 
X 
X 
X 
 
X 
PGA 
X 
X 
X 
 
X 
Medication assessment 
X 
X 
X 
X 
X 
Events of interest assessment  
 
X 
X 
X 
X 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
34 
6 
ENROLLMENT AND RANDOMIZATION 
6.1 
Enrollment 
Eligible subjects who have given written informed consent and meet all inclusion and no 
exclusion criteria will be randomized.  
6.2 
Randomization 
After signing the informed consent form, all subjects who fulfill all of the inclusion 
criteria and none of the exclusion criteria will be randomized. All patients will be 
randomized using an electronic system in a 1:1 allocation ratio to either predischarge 
initiation of ivabradine or usual care. Randomization will be stratified by clinical site.  

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
35 
7 
PARTICIPANT SAFETY 
7.1 
Patient Safety and Concomitant Therapies 
This study will evaluate and compare pre-discharge initiation of ivabradine versus usual 
care in patients stabilized after an acute HF exacerbation requiring hospitalization. 
Although investigators are encouraged to follow the assigned treatment strategy, in all 
cases the patient’s safety based on the clinical judgment of the treating physician will 
take priority over the specific treatment assignment. Concomitant therapies will be at the 
discretion of the treating physician. All subjects will receive standard of care which can 
be adjusted by their usual care provider(s) during the study according to clinical need. 
Usual care providers will be encouraged to follow the most up to date guidelines for 
cardiovascular care based upon local and institutional practice patterns and relevant 
published practice guidelines. 
7.2 
Institutional Review Boards  
All sites will submit the study protocol, informed consent form, and other relevant study 
documents to their Institutional Review Board (IRB) for approval.  
7.3 
Informed Consent  
All patients will have the purpose of the study, the study interventions and evaluations, 
and the potential risks and benefits of participation explained to them and their questions 
answered. If they consent to participation in this study, they will review and sign the 
informed consent form. 
7.4 
Study Discontinuation  
Subjects may withdraw at any time during the study without prejudice or be discontinued 
from study treatment at the discretion of the investigator if medically necessary. In 
addition, a subject may be withdrawn by the investigator or the sponsor if the subject 
violates the study plan or for administrative and/or other safety reason.  

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
36 
The investigator or designee will document in the eCRF when a subject has been 
discontinued or withdrawn from study treatment because of an adverse experience. When 
a subject discontinues or is withdrawn from treatment before study completion, all 
applicable activities scheduled for the final study visit should be performed at the time of 
discontinuation. Any adverse experiences that are present at the time of 
discontinuation/withdrawal should be followed by the site PI until resolution. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
37 
8 
ADVERSE EVENT REPORTING AND FOLLOW-UP 
8.1 
Safety 
In this study, all medications and procedures commonly used or performed as a part of 
standard of care for the management of HF have well-defined safety profiles. For this 
trial, defined clinical endpoints and events of interest will be recorded in the eCRF. In 
addition, events that are Serious and Unexpected will be reported by a site investigator to 
the local IRB per the IRB’s instructions and will be the subject of a MedWatch report, 
based on local requirements. 
 
The investigator is responsible for monitoring the safety of subjects enrolled into the 
study at the study site. The investigator or qualified designee will enter the required 
initial and follow-up information regarding events into the appropriate module of the 
eCRF.  Investigators are to report serious adverse events in accordance with their local 
IRB requirements. Investigators should follow usual clinical practices at their institution 
for reporting to regulatory authorities serious, unexpected events related to standard of 
care medications and devices.  
8.2 
Definitions 
8.2.1 Events of Interest 
Sites will record in the eCRF Events of Interest which include 
1) Symptomatic bradycardia 
2) Symptomatic hypotension 
3) Other symptoms leading to ivabradine discontinuation 
4) Any Adverse Event that, in the opinion of the site investigator, is related to 
ivabradine and is:  
a) Serious, and  
b) Unexpected 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
38 
8.3 
Protocol Specific Exceptions to SAE Reporting 
The following events will be collected in the CRF but are not the subject of a MedWatch 
report. These events will be captured on anticipated/disease related events pages, not on 
the SAE eCRF page.  Anticipated, disease related-event in patients with acute 
decompensated heart failure include: 
• 
Ventricular tachycardia  
• 
Atrial fibrillation  
• 
Myocardial infarction  
• 
Acute coronary syndrome  
• 
Acute renal failure  
• 
Worsening heart failure  
• 
Death  
 
With the exception of the events listed above, all serious adverse events the site PI 
determines to be related to ivabradine must be recorded in the Serious Adverse Event 
eCRF and  should be monitored until stabilization or resolution.  
 
Site investigators are responsible for knowing the local requirements for prompt reporting 
of an adverse event to the reviewing IRB/EC and for reporting an SAE to FDA via a 
MedWatch.  
An Independent Data and Safety Monitoring Board (DSMB) will review safety composite 
data at regular intervals throughout the study. The DSMB will be empowered to stop the 
study for evidence of harm but not for evidence of efficacy.  
8.3.1 Suspected Adverse Reaction 
In PRIME-HF a suspected adverse reaction (SAR) is any AE for which there is a 
reasonable possibility that ivabradine caused the event. “Reasonable possibility” suggests 
there is a causal relationship between the drug and the AE. “Suspected adverse reaction” 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
39 
implies a lesser degree of certainty about causality than adverse reaction, which means 
any AE caused by a drug. 
8.4 
Assessment of Adverse Event Severity  
The determination of AE severity rests on medical judgment of a medically qualified 
investigator. The severity of AEs will be graded using the following definitions:  
 Mild: Awareness of sign, symptom, or event, but easily tolerated. 
 Moderate: Discomfort enough to cause interference with usual activity and 
may warrant intervention. 
 Severe: Incapacitating with inability to do usual activities or significantly 
affects clinical status and warrants intervention. 
8.5 
Assessment of Causal Relationship 
A medically qualified investigator must assess the relationship of any AE to the use of 
study drug, based on available information, using the following guidelines: 
 Not related: There is not a reasonable causal relationship between the 
investigational product and the AE.  
 Unlikely related: No temporal association or cause of the event has been 
identified, or the drug or biologic cannot be implicated. 
 Possibly related: There is reasonable evidence to suggest a causal 
relationship between the drug and AE. 
 Probably related: There is evidence to suggest a causal relationship between 
the drug and AE, and the influence of other factors is unlikely. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
40 
8.6 
Expectedness 
The Investigative site PI or designee will determine expectedness of an SAE according to 
the package insert for U.S. marketed ivabradine. Any SAE that is not identified in nature, 
severity, or specificity in the current study drug reference documents is considered 
unexpected. Events that are listed in the package insert as occurring with a class of drugs 
or as anticipated from the pharmacological properties of the drug, but not specifically 
listed as occurring with the particular drug under investigation, are considered 
unexpected. As per the ivabradine package insert, the most common adverse reactions 
occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and 
luminous phenomena (phosphenes). 
8.7 
Adverse Event Reporting 
All SAEs obtained via direct subject reporting and/or clinical staff observation that the 
site PI determined to be related to ivabradine will be captured within the electronic case 
report form (eCRF). 
8.8 
Serious Adverse Events 
The investigator must record, via the EDC system, all SAEs that the site PI determined to 
be related to ivabradine occurring at visit 1 through visit 3 within 24 hours of knowledge 
of the event. If the eCRF system is temporarily unavailable, notify the sponsor or 
designee of the event, including investigator-determined causality assessment, via a paper 
back-up SAE form. Upon return of the availability of the EDC system, the SAE 
information must be entered into the eCRF. 
 
The investigator must record in the EDC system when important follow-up information 
(final diagnosis, outcome, results of specific investigations, etc.) becomes available after 
submission of the initial SAE information. Follow-up information should be submitted 
according to the same process used for reporting the initial event as described above (i.e., 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
41 
within 24 hours of knowledge, via the EDC system). All SAEs will be followed until 
resolution, stabilization, until otherwise explained.  
 
Research sites are expected to follow local IRB policies and procedures for reporting 
AEs/SAEs.  
8.9 
Pregnancy 
During the course of the trial, if any female subject who is receiving ivabradine becomes 
pregnant, or if any person is exposed to ivabradine by a lactating female subject, this 
information will be recorded in the eCRF and reported via the pregnancy form.  While a 
subject’s pregnancy is not considered an SAE, it must be reported within the same 
timelines as an SAE (within 24 hours).  Any AEs or SAEs associated with ivabradine that 
occur to the female subject or fetus/child will be recorded in the eCRF on the AE or SAE 
form, as appropriate. 
8.10 Withdrawal of Subjects from Study 
Subjects have the right to withdraw from the study at any time and for any reason without 
prejudice to future medical care. In the case of subject withdrawal, the investigator will 
discuss with the subject the most appropriate way to terminate study participation to 
ensure the subject’s health. All efforts will be made to complete and report the 
observations as thoroughly as possible up to the date of study termination. All applicable 
activities scheduled for the final study visit should be preformed at the time of 
discontinuation. Randomized subjects who withdraw from the study will not be replaced.  
 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
42 
9 
SUMMARY OF CLINICAL EVENTS 
Additional data on clinical events of interest will be collected. 
a. Worsening HF defined as either hospital admission for worsening signs and/or 
symptoms of HF or receiving unplanned intravenous (IV) diuretics for HF as 
an outpatient. 
b. All-cause mortality 
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
43 
10 STATISTICAL ANALYSIS PLAN AND DETERMINATION OF SAMPLE 
SIZE 
10.1 Overview 
All planned analyses will be prospectively defined for this study and approved by the 
Steering Committee. In addition, exploratory analyses will be performed to help explain 
and understand findings observed from the planned analyses. Statistical tests with a 2-
sided p-value <0.05 will be considered statistically significant, unless otherwise stated. 
Analyses will be performed using SAS software (SAS Institute, Inc, Cary, NC).  
The primary endpoint of the study is proportion of participants using ivabradine at 180 
days.  
10.2 Sample Size Justification 
We assumed that 35% of participants randomized to the usual care arm will be treated 
with ivabradine at 180 days, and the predischarge initiation of ivabradine would increase 
the use at 180 days to 50%. The usual care event rate is based on investigator estimates of 
clinical use in the first year following approval by the Food and Drug Administration. At 
a two-sided Type I error rate of 0.05, 450 participants would provide 85% power to 
detect a significant difference in the rate of ivabradine use between groups. This sample 
size estimate is based on a two-group continuity corrected chi-square test and assumes a 
1:1 allocation ratio between the predischarge initiation of ivabradine and usual care 
groups. This sample size estimate allows for 8% missing primary endpoint data. 
 
For the KCCQ overall summary endpoint we have made a conservative assumption of 16 
points for the standard deviation.  For this measure, the medium and large clinically 
meaningful differences are 5 and 10 points for the KCCQ overall summary measure, 
respectively. Allowing for approximately 8% missing data, the proposed sample size of 
450 participants provides approximately 90% power to detect a difference of 5 points 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
44 
(medium clinically meaningful difference). The power calculations are based on the two 
sample t-test with a two-sided Type I error rate of 0.05.  
10.3 Analysis of the Primary Endpoint 
The primary analysis will be conducted on an intention-to-treat (ITT) basis including all 
randomized participants. A logistic regression model with ivabradine use at 180 days as 
the binary outcome variable and indicator variables for treatment group main effects and 
category of baseline beta-blocker use. The treatment effect for the ivabradine at discharge 
group will be summarized by the odds ratio and the associated 95% confidence interval.  
10.4 Analysis of Secondary and Tertiary Endpoints 
 Heart Rate Assessments 
o Change in heart rate from baseline to 180 days across treatment groups. 
Change will be calculated as follows: (Baseline heart rate – 180-day heart 
rate). Comparisons across treatment groups will be performed using a 
linear model with adjustment for the baseline heart rate and beta-blocker 
use.  Treatment groups will be included in the regression model as main 
effects. Multiple imputation will be used to impute 180-day missing HR 
observations if missing is > 10%. 
o Heart rate in bpm at 180 days will be compared in the predischarge 
ivabradine group compared across treatment groups. Comparisons across 
treatment groups will be performed using a linear model with adjustment 
for the baseline heart rate and beta-blocker use.  Treatment groups will be 
included in the regression model as main effects. Multiple imputation will 
be used to impute 180-day missing HR observations if missing is > 10%. 
 Changes in symptoms and quality-of-life from baseline to 180 days as assessed by 
KCCQ and PGA will be evaluated across treatment groups using a linear model 
with adjustment for the baseline quality-of-life and beta-blocker use. A multiple 
imputation approach will be used to account for possible missing data. The 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
45 
differences between treatment groups will be estimated using point estimates and 
the associated two-sided 95% confidence intervals. 
 Beta-blocker use at 180 days as assessed by the (a) proportion of participants on a 
beta-blocker at 180-days, (b) proportion on target dose, (c) the proportion 
discontinuing beta-blockers at 180 days and (d) the mean change in beta-blocker 
dose from discharge to 180 days will be compared between treatment groups. 
 Ivabradine use at 180 days as assessed by the (a) proportion of appropriate 
participants with any initiation of ivabradine at 180 days, (b) the proportion of 
appropriate participants at the maximum dose of ivabradine at 180 day (i.e., 7.5 
mg twice daily), and (c) the mean dose of ivabradine achieved at 180 days will be 
compared between treatment groups. 
 The event counts and subject incidences for the following adverse events will be 
presented for the treatment groups: 
o Symptomatic bradycardia 
o Symptomatic hypotension 
 Barriers to the acquisition of ivabradine. Barriers will be documented in the case 
report form and reported in tabular format. 
10.5 Interim Analyses 
Interim data analysis for efficacy will not be conducted due to modest size and short 
duration of this study. Safety data will be periodically assessed by the DSMB. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
46 
11 DATA MONITORING AND QUALITY CONTROL 
11.1 Required Data 
The full study dataset will be collected for subjects who enter the randomization phase of 
the study. Limited data as available (i.e., demographics, serious adverse events related to 
ivabradine, selection criteria, and reason for discontinuation) will be collected for subjects 
who discontinue before the end of the protocol specified follow-up period. 
All required data for this study will be entered into the electronic case report form (eCRF). 
11.2 Data Collection and Tracking 
Qualified study staff at each site will perform primary data collection from source-
document reviews. The sponsor or designee will perform clinical monitoring, including 
review of eCRFs with verification to the source documentation. 
This study will use Web-based e-CRFs developed through a validated, electronic reporting-
electronic-signatures–compliant platform (21 Code of Federal Regulations Part 11). The 
investigator's site staff who will be entering data will receive training on the system, after 
which each person can set up their database account and request study access 
For security reasons, and in compliance with regulatory guidelines, it is imperative that 
only the persons who own the user IDs and passwords access the system using their own 
unique access codes. Access codes are nontransferable. Site personnel who have not 
undergone training may not use the system and will not be granted access to the clinical 
database until appropriate training is completed. 
During monitoring visits, the site will make their computer and/or high-speed Internet 
access available to the clinical research associate, so that he or she may verify the data 
entries with the source documentation. At the conclusion of the study, each enrolling site 
will be provided with a thumb drive containing PDF files of both the individual subject's 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
47 
data and the audit trail (changes made to the database). This will be maintained at the site 
according to the requirements for records retention. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
48 
12 Study Responsibilities 
12.1 Investigator Responsibility/Performance 
The site principal investigator (PI) agrees to be responsible for implementing and 
maintaining quality control and quality assurance systems to ensure that all work incidental 
to this protocol is conducted and data are generated, documented, and reported in 
compliance with: the protocol; accepted standards of Good Clinical Practice (GCP); and 
all applicable federal, state, and local laws, rules and regulations relating to the conduct of 
the clinical study. 
The PI will provide current copies of the study protocol to all subinvestigators or other site 
personnel responsible for study conduct. 
The PI will provide the sponsor or designee with copies of all institutional review board 
(IRB) actions regarding the study. 
12.2 Study Data Reporting and Processing 
Each page of the electronic case report form (eCRF) will be reviewed by PI at the site. The 
PI is required to sign the eCRF on the appropriate pages to verify that he or she has 
reviewed the recorded data. This review and sign-off may be delegated to a qualified 
physician appointed as a subinvestigator by the PI. The transfer of duties to a 
subinvestigator will be recorded on the delegation list, which is kept on file at the site. The 
investigator must ensure that all site staff involved in the conduct of the trial are familiar 
with the protocol and all study-specific procedures, and that they have appropriate 
knowledge of the study agents. 
12.3 Training 
The initial training of appropriate clinical site personnel will be the responsibility of  the 
sponsor or designee. The PI is responsible for ensuring that staff conduct the study 
according to the protocol. To ensure proper administration of study agents, uniform data 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
49 
collection, and protocol compliance, the sponsor or designee will present a formal 
training session to study site personnel, to include instructions for study procedures, the 
investigational plan, instructions on in-hospital data collection, methods for soliciting 
data from alternative sources, schedules for follow-up with the study site coordinators, 
and regulatory requirements. Detailed feedback regarding completion of forms will be 
provided by the sponsor ot designee in the course of  monitoring. 
12.4 Monitoring the Investigational Sites 
As part of a concerted effort to follow the study in a detailed and orderly manner in 
accordance with established principles of GCP and applicable regulations, a study monitor 
from the sponsor or designee will visit the study sites as appropriate and will maintain 
frequent telephone and written communication. 
Periodic monitoring visits may be made at all active investigational sites throughout the 
clinical study as needed to assure that the investigator obligations are being fulfilled and 
all applicable regulations and guidelines are being followed. The goal of these visits are to 
assure the facilities are still acceptable, the protocol and investigational plan are being 
followed, the IRB/EC has been notified of approved protocol changes as required, 
complete records are being maintained, appropriate  reports have been made to the sponsor 
or designee and the IRB/EC, and the investigator is carrying out all agreed-upon activities. 
During monitoring visits, the monitor will perform a review of  inclusion/exclusion criteria, 
informed consent, HIPAA authorization, events of interest , as well as safety and efficacy 
endpoints. Additional review will be performed on a site-by-site basis, as warranted by the 
findings of previous monitoring visits. Key variables will be confirmed through review of 
source documents for a sampling of patients.  
Sites may be required to provide at a minimum the informed consent and discharge 
summary for subjects to the the sponsor or designee via a secure system.  

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
50 
Trends will be monitored and, if warranted, the frequency of onsite monitoring visits may 
be adjusted at sites.  Details will be described in the clinical monitoring plan. 
12.5 Study Documentation 
Study documentation includes all electronic  case report forms, source documents, 
monitoring logs and appointment schedules, sponsor-investigator correspondence, and 
regulatory documents (e.g., protocol and amendments, IRB or EC correspondence and 
approval, approved and signed subject consent forms,  clinical supplies receipts and 
distribution records). 
The site PI will prepare and maintain complete and accurate study documentation in 
compliance with GCP standards and applicable federal, state, and local laws, rules and 
regulations. For each subject participating in the study at the site, the investigator will 
promptly complete all eCRFs and such other reports as required by this protocol following 
completion or termination of the clinical study or as otherwise required pursuant to any 
agreement with the sponsor. 
The site PI acknowledges that, within legal and regulatory restrictions and institutional and 
ethical considerations, study documentation will be promptly and fully disclosed to the 
sponsor or designee by the investigator upon request and also shall be made available at 
the investigator’s site upon request for inspection, copying, review, and audit at reasonable 
times by representatives of the sponsor or responsible government agencies as required by 
law.  
The PI agrees to promptly take any reasonable steps that are requested by the sponsor or 
designee as a result of an audit to cure deficiencies in the study documentation and eCRFs. 
12.6 Source Documentation 
Source documents include all recordings of observations or notations of clinical activities 
and all reports and records necessary for the evaluation and reconstruction of the clinical 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
51 
study. Accordingly, source documents include, but are not limited to, laboratory reports, 
electrocardiogram (ECG) tracings, x-rays, radiologist reports, subject diaries, biopsy 
reports, ultrasound photographs, subject progress notes, hospital charts, pharmacy records, 
and any other similar reports or records of any procedure performed in accordance with the 
protocol. 
Whenever possible, the original recording of an observation should be retained as the 
source document; however, a photocopy is acceptable provided that it is a clear, legible, 
and exact duplication of the original document. 
The following information will be maintained and made available as required by the 
sponsor or designee and/or regulatory inspectors: 
1. Medical history/physical condition of the study subject before involvement in 
the study sufficient to verify protocol entry criteria. 
2. Documentation that informed consent was obtained for the subject’s 
participation in the study. 
3. Dated and signed notes for each subject visit, including results of 
examinations. 
4. Notations on abnormal laboratory results and their resolution. 
5. Dated printouts or reports of special assessments (e.g., ECG reports). 
6. Description of adverse events (AEs) and follow-up of the AEs (minimally, 
event description, severity, onset date, duration, relation to study drug, 
outcome, and treatment for AE). 
7. Notes regarding concomitant medications taken during the study (including 
start and stop dates). 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
52 
8. Subject’s condition upon completion of or withdrawal from the study. 
12.7 Protocol Deviations 
A protocol deviation is defined as an event where the investigator or site personnel did not 
conduct the study according to the investigational plan. Site investigators must also follow 
the policy of the reviewing IRB for reporting such deviations. to their reviewing IRB per 
local policy. 
The IRB/EC will be informed of all protocol changes by the sponsor or the investigator in 
accordance with applicable regulations and the IRB/EC’s established procedures. No 
deviations from the protocol of any type will be made without complying with the 
IRB/EC’s established procedures. 
Investigators will maintain documentation of the dates and reasons for each deviation from 
the protocol. 
12.8 Data Transmittal and Record Retention 
Required data will be entered in the eCRF at the time of or as soon as possible after the 
subject visit or the availability of test results 
The PI will maintain  final eCRFs, worksheets, and all other study-specific documentation 
(e.g., study file notebooks or source documentation) until notified by the sponsor that 
records may be destroyed. To avoid error, the investigator will contact the sponsor or 
designee before the destruction of any records pertaining to the study to ensure they no 
longer need to be retained. In addition, the sponsor or designee will be contacted if the PI 
plans to leave the institution so that arrangements can be made for the transfer of records. 
The site PI takes responsibility for maintaining adequate and accurate source documents of 
all observations and data generated during this study. Such documentation is subject to 
inspection by the sponsor or designee as well as by federal, state, and local regulatory 
agencies. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
53 
12.9 Study Closeout 
Upon completion of the study (defined as all subjects have completed all follow-up visits, 
all eCRFs are complete, and all queries have been resolved), the sponsor or designee will 
notify the site of closeout, and a study closeout visit will be performed. All unused study 
materials can be destroyed by the site when the study is completed. The sponsor or designee 
will ensure that the PI’s regulatory files are up-to-date and complete and that any 
outstanding issues from previous visits have been resolved. Other issues to be reviewed at 
the closeout visit include discussing retention of study files, possibility of site audits, 
publication policy, and notifying the IRB of study closure. 
12.10 Audit/Inspections 
As needed, quality assurance personnel from the sponsor or designee may conduct audits 
at the study sites at a reasonable time and in a reasonable manner. Audits will include, but 
not be limited to, audit trail of data handling and processes, standard operating procedures, 
presence of required documents, the informed consent process, and comparison of eCRFs 
with source documents. The site PI agrees to accommodate and participate in audits that 
are conducted. 
Regulatory authorities from the U.S. or abroad may inspect the site during or after the study 
at a reasonable time and in a reasonable manner. The PI should contact the sponsor 
immediately if contacted regarding an inspection. Site personnel are expected to cooperate 
with personnel from regulatory agencies (e.g., FDA) audits conducted  
12.11 Publication Policies 
Members of the Steering Committee will be primarily responsible for creation, review, and 
submission of publications and presentations relating to the major aspects of the study and 
approved ancillary analyses within a timely fashion after completion of the study. Details 
will be contained in the Publication Plan.  
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
54 
13 Ethical Considerations 
13.1 Informed Consent 
The PI has both ethical and legal responsibility to ensure that each subject being considered 
for inclusion in this study is given a full explanation of the study. Written informed consent 
will be obtained from all subjects (or, at the discretion of the local IRB, the subject’s 
guardian or legally authorized representative [LAR]) before any study-related procedures  
are performed or given.  
Written informed consent will be documented on an informed consent form (ICF) approved 
by the local IRB/EC responsible for approval of this protocol. The ICF will conform to the 
applicable requirements of 45 CFR 46, ICH E6 and institutional requirements for informed 
consent.  The site investigator agrees to obtain approval from the sponsor of any ICF 
intended for use in the study before submission of the ICF for IRB approval. 
The ICF will be reviewed with the prospective study subject (or LAR), and the investigator 
or qualified designee will be available to answer questions regarding procedures, risks, and 
alternatives.  
13.2 Confidentiality of Subjects 
Subject confidentiality will be maintained throughout the clinical study in a way that 
ensures that study data can always be tracked back to the source data.  
Subject information collected in this study will comply with the standards for protection of 
privacy of individually identifiable health information as promulgated by the U.S. Health 
Insurance Portability and Accountability Act (HIPAA). All records will be kept 
confidential, and the subject’s name will not be released to persons outside the study site. 
Subject records will not be released to anyone other than the sponsor or its designees and 
responsible regulatory authorities when requested. In all cases, caution will be exercised to 
assure the data are treated confidentially and that the subject’s privacy is guaranteed. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
55 
13.3 Authorization for Use and Disclosure of Protected Health Information 
(HIPAA) 
An authorization for use and disclosure of protected health information (PHI) under the 
HIPAA Privacy Rule will be obtained from every trial subject before enrollment. The 
investigator is responsible for obtaining subjects’ (or their LARs’) authorizations and 
signatures and for explaining the elements of the HIPAA authorization form, if necessary. 
The site PI will promptly inform the sponsor of any restrictions on the use or disclosure of 
any subject’s PHI. The site investigator will also promptly inform the sponsor of written 
revocation of any subject’s HIPAA authorization. 
13.4 Human Subject Protections 
13.4.1 Research Subject Selection and Justification of Exclusions 
There will be no exclusion from participation in the study on the basis of ethnicity or race. 
Subjects younger than 18 years of age will be excluded from the study, as the target 
population is adults. Women of childbearing potential will have serum-hCG testing before 
randomization to avoid potential fetal exposure to ivabradine.  
13.4.2 Risks/Discomforts of Study Participation 
This study will evaluate the safety and efficacy of ivabradine following stabilization for 
acute HF. Oral ivabradine was found to be safe and efficacious in chronic HF patients in 
the SHIFT trial over a median follow-up of 22.9 mos. In SHIFT, the overall rate of SAEs 
was similar between the ivabradine and placebo arms; ivabradine was not associated with 
any evidence of harm over this follow-up period.  
13.5 Institutional Review Board/Ethics Committee Review 
The appropriate IRB/EC must approve the protocol and informed consent documents, 
agree to monitor the conduct of the study, and agree to review study progress periodically, 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
56 
at intervals not to exceed 1 year. The investigator will provide the sponsor or designee with 
documentation that the IRB/EC has approved the study before the study may begin. 
In addition, the investigator must provide the following documentation to DCRI: 
1. IRB/EC annual reapproval of the protocol,. 
2. IRB/EC approval of revisions to the informed consent documents or any 
amendments to the protocol. The investigator will provide the sponsor or 
designee with documentation of all approvals. 
13.6 Steering Committee 
The Steering Committee will be the primary decision making body of the study and is 
responsible for its successful completion. The Steering Committee will be comprised of 
the study principal investigators, the project leader, and selected other investigators with 
expertise in heart failure and clinical trials.  
13.7 Data and Safety Monitoring Board 
A data and safety monitoring board (DSMB) will be appointed for the PRIME-HF trial, 
which will include individuals with pertinent expertise in heart failure and clinical trials. 
The DSMB will advise the Steering Committee regarding  safety concerns for current 
participants and those yet to be recruited.  
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
57 
14 Appendices 
Appendix A. Safety Considerations 
Similar to the SHIFT study, the following treatments are not allowed at inclusion or 
during the study: 
 
Non-dihydropyridine calcium channel blockers (e.g., diltiazem and verapamil) 
 
Class I anti-arrhythmics (e.g., quinidine, procainamide, lidocaine, phenytoin) 
 
Strong inhibitors of cytochrome P450 3A4 (CYP3A4), including some macrolide 
antibiotics (e.g., clarithromycin, erythromycin), cyclosporine, antiretroviral drugs 
(e.g., ritonavir, nelfinavir), and systemic azole antifungal agents (e.g., 
ketoconazole, itraconazole)  
 
Inducers of cytochrome P450 3A4 (CYP3A4) including St. John’s Wort, 
rifampicin, barbiturates, and phenytoin 
 
Treatments known to be associated with significant prolongation of the QT 
interval, including sotalol 
  
 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
58 
Appendix B. Cardiomyopathy Questionnaire and Patient Global Assessment  
Kansas City Cardiomyopathy Questionnaire  
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-administered, 23-item 
questionnaire developed to provide a better description of health-related quality of life 
(QOL) in patients with heart failure. It quantifies physical limitation, symptoms, QOL, 
social interference and self-efficacy. The survey requires 4-6 minutes to complete, and is 
scored by assigning each response an ordinal value, beginning with 1 for the response 
that implies the lowest level of functioning and summing items within each domain. 
Scale scores are transformed to a 0 to 100 range by subtracting the lowest possible scale 
score, dividing by the range of the scale and multiplying by 100. A clinical summary 
score will be calculated by combining the functional status with the quality of life and 
social limitation domains.  
 
Patient Global Assessment  
A seven category global assessment of clinical status that is completed by the participant 
will be utilized in the assessment of the composite score. This Patient Global Assessment 
(PGA) tool consists of the categories of: markedly improved, moderately improved, 
mildly improved, no change, slightly worse, moderately worse and markedly worse.  
Participants will be asked to define their status using this tool at specified times during 
the protocol by marking their current status, relative to the baseline condition. The Patient 
Global Assessment tool will be prepared in a manner which is simple to read (large print) 
and will be retained as a source document. 
 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
59 
References  
1. 
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics—
2015 Update: A Report From the American Heart Association. Circulation. 
2015;131(4):e29-e322. 
2. 
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the 
Management of Heart Failure: A Report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 
2013;128(16):e240-e327. 
3. 
Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. 
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart 
failure: results of the Initiation Management Predischarge: Process for Assessment of 
Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. Journal of the American 
College of Cardiology. 2004;43(9):1534-1541. 
4. 
Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic 
heart failure (SHIFT): a randomised placebo-controlled study. The 
Lancet.376(9744):875-885. 
5. 
Braunwald E. Heart failure. JACC: Heart Failure. 2013;1(1):1-20. 
6. 
Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in 
heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. 
JAMA : the journal of the American Medical Association. 2011;306(15):1669-1678. 
7. 
Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart Failure 
Incidence and Survival (from the Atherosclerosis Risk in Communities Study). The 
American journal of cardiology. 2008;101(7):1016-1022. 
8. 
Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care 
indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 
2005;165(13):1469-1477. 
9. 
Peterson PN, Chan PS, Spertus JA, et al. Practice-level Variation in Use of 
Recommended Medications Among Outpatients With Heart Failure: Insights From the 
NCDR PINNACLE Program. Circulation: Heart Failure. 2013. 

Amgen Proprietary - Confidential 
PRIME-HF 
 
 
 
 
Confidential 
Version 3 – July 19, 2017 
 
60 
10. 
Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich 
PA. Potential impact of optimal implementation of evidence-based heart failure therapies 
on mortality. American heart journal. 2011;161(6):1024-1030.e1023. 
11. 
Members ATF, McMurray JJV, Adamopoulos S, et al. ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the 
Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European 
Society of Cardiology. Developed in collaboration with the Heart Failure Association 
(HFA) of the ESC. European Heart Journal. 2012;33(14):1787-1847.